|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Felodipine#Clinical Studies]] |
| {{Felodipine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Clinical Studies==
| |
| | |
| Felodipine produces dose-related decreases in systolic and diastolic blood pressure as demonstrated in six placebo-controlled, dose response studies using either immediate-release or extended-release dosage forms. These studies enrolled over 800 patients on active treatment, at total daily doses ranging from 2.5 to 20 mg. In those studies felodipine was administered either as monotherapy or was added to beta blockers. The results of the 2 studies with PLENDIL given once daily as monotherapy are shown in the table below:
| |
| | |
| {|
| |
| |[[File:felodipine03.jpg|thumb|800px]]
| |
| |}
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLENDIL (FELODIPINE) TABLET, EXTENDED RELEASE [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aad9cdf-6431-4661-5cb4-f69e735f47e4 | publisher = | date = | accessdate = 28 February 2014 }}</ref>
| |
| | |
| | |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Calcium channel blockers}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Dihydropyridines]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |